ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0042

Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model

Eva Philippon1, Jan Piet van Hamburg1, Lisanne van Rooijen1, Gary Sims2, Conny Van der Laken3 and Sander Tas4, 1Amsterdam UMC, Amsterdam, Netherlands, 2Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 3Amsterdam UMC - location VUMC, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

Meeting: ACR Convergence 2024

Keywords: Angiogenesis, Fibroblasts, Synovial, Inflammation, macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell proliferation, angiogenesis and extensive immune cell infiltration in the synovium.  In vitro approaches that replicate the complex cell interactions within RA synovial tissue are essential for preclinical and translational research. These models enhance our understanding of RA pathophysiology and help in the development of new diagnostic and therapeutic strategies. Recently, we developed a novel RA synovial tissue spheroid-based model that integrates RA fibroblast-like-synoviocytes (RAFLS), endothelial cells (ECs), and macrophages, allowing for the study of both angiogenesis and inflammatory processes. 

In this study, we examined the potential of the 3D model, incorporating either inflammatory “M1”-like or anti-inflammatory “M2”-like macrophages, to modulate key RA inflammatory processes. We used established anti-TNF therapies and novel small molecule inhibitors of the NF-κB signaling pathways.

Methods: We created spheroids composed of RAFLS, ECs and either M1 or M2 macrophages derived from monocytes. These spheroids were cultured in a collagen-based matrix and exposed to various conditions: pro-angiogenic factors (VEGF/bFGF), the pro-inflammatory cytokine TNFα, or RA synovial fluid (SF). The impact of macrophage phenotype on spheroid outgrowth, macrophage containment, and cytokine production was quantified using confocal imaging and digital image analysis by machine learning, and ELISA for measuring pro-inflammatory soluble factors in culture supernatants. Finally, therapeutic compounds were tested in the 3D model with M1 macrophages in the presence of GF, SF or TNF using the same readouts.

Results: M2 macrophages exhibited greater migration away from the spheroid core compared to M1 macrophages in all conditions. SF significantly enhanced  the containment of M1 macrophages within the spheroid core, a result not observed with the M2 macrophages. The inhibitor of κB Kinase (IKKβi) reduced spheroid outgrowth (~50%) in the model with M1 macrophages under GF stimulation, while the NF-κB-inducing kinase (NIK) inhibitor fully prevented spheroid outgrowth compared to the unstimulated condition. Both TNF inhibitors, etanercept (ETA) and certolizumab pegol (CP), reduced interleukin (IL)-6 production to levels comparable to unstimulated conditions upon GF stimulation. TNF stimulation significantly increased IL-6 production, which was strongly inhibited by IKKβi, ETA and CP. None of the compounds affected macrophage containment within the core compared to SF-only conditions.

Conclusion: Our 3D RA synovial tissue effectively replicates alterations in cellular interactions based on macrophage phenotype and demonstrates the inhibitory effects of therapeutic compounds on spheroid outgrowth and soluble mediator production. This model shows the potential for testing the effect of various therapeutic applications on RA synovial inflammation and angiogenesis.


Disclosures: E. Philippon: None; J. van Hamburg: None; L. van Rooijen: None; G. Sims: AstraZeneca, 3; C. Van der Laken: None; S. Tas: None.

To cite this abstract in AMA style:

Philippon E, van Hamburg J, van Rooijen L, Sims G, Van der Laken C, Tas S. Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/modulating-inflammation-and-angiogenesis-in-an-advanced-3d-rheumatoid-arthritis-synovial-tissue-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modulating-inflammation-and-angiogenesis-in-an-advanced-3d-rheumatoid-arthritis-synovial-tissue-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology